352 related articles for article (PubMed ID: 22521285)
21. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
Lieberman JM; Williams WR; Miller JM; Black S; Shinefield H; Henderson F; Marchant CD; Werzberger A; Halperin S; Hartzel J; Klopfer S; Schödel F; Kuter BJ;
Pediatr Infect Dis J; 2006 Jul; 25(7):615-22. PubMed ID: 16804432
[TBL] [Abstract][Full Text] [Related]
22. Measles-mumps-rubella vaccine and autistic spectrum disorder: report from the New Challenges in Childhood Immunizations Conference convened in Oak Brook, Illinois, June 12-13, 2000.
Halsey NA; Hyman SL;
Pediatrics; 2001 May; 107(5):E84. PubMed ID: 11331734
[TBL] [Abstract][Full Text] [Related]
23. [Certain problems with limits of immunity against measles, mumps and rubella].
Magdzik W
Przegl Epidemiol; 1993; 47(1-2):47-53. PubMed ID: 8351387
[TBL] [Abstract][Full Text] [Related]
24. MMR vaccination and disease elimination: the Finnish experience.
Davidkin I; Kontio M; Paunio M; Peltola H
Expert Rev Vaccines; 2010 Sep; 9(9):1045-53. PubMed ID: 20822347
[TBL] [Abstract][Full Text] [Related]
25. Safety concerns regarding combination vaccines: the experience in Japan.
Andreae MC; Freed GL; Katz SL
Vaccine; 2004 Sep; 22(29-30):3911-6. PubMed ID: 15364439
[TBL] [Abstract][Full Text] [Related]
26. Could the MMR vaccine replace the measles vaccine at one year of age in Egypt?
Abbassy AA; Barakat SS; Abd El Fattah MM; Said ZN; El Metwally HA
East Mediterr Health J; 2009; 15(1):85-93. PubMed ID: 19469430
[TBL] [Abstract][Full Text] [Related]
27. Differences in persistence of measles, mumps, rubella, diphtheria and tetanus antibodies between children with rheumatic disease and healthy controls: a retrospective cross-sectional study.
Heijstek MW; van Gageldonk PG; Berbers GA; Wulffraat NM
Ann Rheum Dis; 2012 Jun; 71(6):948-54. PubMed ID: 22172491
[TBL] [Abstract][Full Text] [Related]
28. Measles, mumps and rubella infections and atopic disorders in MMR-unvaccinated and MMR-vaccinated children.
Bernsen RM; van der Wouden JC
Pediatr Allergy Immunol; 2008 Sep; 19(6):544-51. PubMed ID: 18266826
[TBL] [Abstract][Full Text] [Related]
29. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program.
Peltola H; Heinonen OP; Valle M; Paunio M; Virtanen M; Karanko V; Cantell K
N Engl J Med; 1994 Nov; 331(21):1397-402. PubMed ID: 7969278
[TBL] [Abstract][Full Text] [Related]
30. Encephalopathy after whole-cell pertussis or measles vaccination: lack of evidence for a causal association in a retrospective case-control study.
Ray P; Hayward J; Michelson D; Lewis E; Schwalbe J; Black S; Shinefield H; Marcy M; Huff K; Ward J; Mullooly J; Chen R; Davis R;
Pediatr Infect Dis J; 2006 Sep; 25(9):768-73. PubMed ID: 16940831
[TBL] [Abstract][Full Text] [Related]
31. MMR vaccination: new thought.
Deshmukh V
Indian Pediatr; 2006 Jun; 43(6):555-6. PubMed ID: 16820670
[No Abstract] [Full Text] [Related]
32. Opportunistic MMR vaccination for unimmunized children at the time of routine teenage booster vaccination in secondary schools: implications for policy.
Paranthaman K; Bunce A
Epidemiol Infect; 2012 Sep; 140(9):1612-6. PubMed ID: 22117122
[TBL] [Abstract][Full Text] [Related]
33. Influence of MMR-vaccinations and diseases on atopic sensitization and allergic symptoms in Swiss schoolchildren.
Roost HP; Gassner M; Grize L; Wüthrich B; Sennhauser FH; Varonier HS; Zimmermann H; Braun-Fahrländer Ch;
Pediatr Allergy Immunol; 2004 Oct; 15(5):401-7. PubMed ID: 15482514
[TBL] [Abstract][Full Text] [Related]
34. The effectiveness of the mumps component of the MMR vaccine: a case control study.
Harling R; White JM; Ramsay ME; Macsween KF; van den Bosch C
Vaccine; 2005 Jul; 23(31):4070-4. PubMed ID: 15950329
[TBL] [Abstract][Full Text] [Related]
35. The virtual elimination of rubella and mumps from the United States and the use of combined measles, mumps and rubella vaccines (MMR) to eliminate measles.
Bart KJ; Orenstein WA; Hinman AR
Dev Biol Stand; 1986; 65():45-52. PubMed ID: 3104117
[TBL] [Abstract][Full Text] [Related]
36. Correlates of lymphoproliferative responses to measles, mumps, and rubella (MMR) virus vaccines following MMR-II vaccination in healthy children.
Dhiman N; Ovsyannikova IG; Jacobson RM; Vierkant RA; Pankratz VS; Jacobsen SJ; Poland GA
Clin Immunol; 2005 May; 115(2):154-61. PubMed ID: 15885638
[TBL] [Abstract][Full Text] [Related]
37. The immunogenicity and reactogenicity of the trivalent vaccine, Trimovax, indicated for prevention of measles, mumps, and rubella, in 12-month-old children in Belarus.
Samoilovich EO; Kapustik LA; Feldman EV; Yermolovich MA; Svirchevskaya AJ; Zakharenko DF; Fletcher MA; Titov LP
Cent Eur J Public Health; 2000 Aug; 8(3):160-3. PubMed ID: 10965439
[TBL] [Abstract][Full Text] [Related]
38. [Measles, mumps and rubella: vaccination rate and seroprevalence in 8th grade students of 8 different sites in Switzerland 1995/96].
Stohrer-Draxl P; Amstad H; Grize L; Gassner M; Takken-Sahli K; Bourquin C; Braun-Fahrländer C
Praxis (Bern 1994); 1999 Jun; 88(24):1069-77. PubMed ID: 10420798
[TBL] [Abstract][Full Text] [Related]
39. The risk of seizures after receipt of whole-cell pertussis or measles, mumps, and rubella vaccine.
Barlow WE; Davis RL; Glasser JW; Rhodes PH; Thompson RS; Mullooly JP; Black SB; Shinefield HR; Ward JI; Marcy SM; DeStefano F; Chen RT; Immanuel V; Pearson JA; Vadheim CM; Rebolledo V; Christakis D; Benson PJ; Lewis N;
N Engl J Med; 2001 Aug; 345(9):656-61. PubMed ID: 11547719
[TBL] [Abstract][Full Text] [Related]
40. Assessment of humoral immunity to poliomyelitis, tetanus, hepatitis B, measles, rubella, and mumps in children after chemotherapy.
Zignol M; Peracchi M; Tridello G; Pillon M; Fregonese F; D'Elia R; Zanesco L; Cesaro S
Cancer; 2004 Aug; 101(3):635-41. PubMed ID: 15274078
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
